Display Settings:

Format

Send to:

Choose Destination

    Vox Sang. 1998;74 Suppl 2:497-8.

    EBV specific CTL: a model for immune therapy.

    Rooney CM, Heslop HE, Brenner MK.

    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA. cmrooney@msmail.his.tch.tmc.edu

    We have been generating Epstein-Barr virus specific cytotoxic T cells for patients at high risk of developing EBV driven lymphoma. To discover the fate of the cells in vivo, we first marked them genetically, using a retroviral vector. Our results in 51 patients show that the approach is safe, that the CTL persist for several years and that they are able to mediate anti-viral and anti-tumor effects. We are now studying other virally-linked malignancies to discover whether a similar approach will be of therapeutic value.

    PMID: 9704488 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read